← Leaderboards
Dean J Burkin
University Of Nevada Reno
$9,739,597
Attributed
$9,739,597
Total exposure
20
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $784.4K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,739,597 · 20
By mechanism
R01$3,591,901 · 3
P20$3,213,970 · 10
R42$1,499,996 · 1
R21$730,271 · 2
R41$674,999 · 3
R13$28,460 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Myopathy”
- Lynn A Sleeper · New England Research Institutes, Inc.$34,307,748
- Ronald M Krauss · University Of Calif-Lawrenc Berkeley Lab$27,234,499
- Jeffrey S Chamberlain · University Of Michigan At Ann Arbor$16,481,575
- Elizabeth M McNally · University Of Chicago$16,273,157
- Conrad C Weihl · Washington University$15,485,311
- Leslie Anne Leinwand · University Of Colorado At Boulder$14,662,510
Research focus
MyopathyMuscleMouse ModelTransgenic OrganismsIntegrinsProteinsAffectPathologyCellsSkeletal Muscle StructureLamininGenesExhibitsDystrophinBaseChildMutationAdultEffective TherapyMuscle CellsMuscle FunctionDisease ProgressionMediatingEmbryo
Grant awards (36)
Laminin protein therapy for the treatment of Laminin-alpha2 deficient congenital muscular dystrophy$403,872
R01 · FY2025 · NS · contact PI
Laminin protein therapy for the treatment of Laminin-alpha2 deficient congenital muscular dystrophy$374,832
R01 · FY2024 · NS · contact PI
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy$752,426
R42 · FY2021 · OD · contact PI
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy$747,570
R42 · FY2020 · OD · contact PI
Laminin protein therapy for Congenital Muscular Dystrophy$315,700
R01 · FY2018 · AR · contact PI
Galectin-1 Protein Therapy for Congenital Muscular Dystrophy$225,000
R41 · FY2018 · AR · contact PI
Laminin protein therapy for Congenital Muscular Dystrophy$325,930
R01 · FY2017 · AR · contact PI
Laminin protein therapy for Congenital Muscular Dystrophy$318,584
R01 · FY2016 · AR · contact PI
Laminin protein therapy for Congenital Muscular Dystrophy$328,035
R01 · FY2015 · AR · contact PI
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy$224,999
R41 · FY2015 · AR · contact PI
Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy$5,143
R41 · FY2015 · AR · contact PI
Laminin protein therapy for Congenital Muscular Dystrophy$315,700
R01 · FY2014 · AR · contact PI
Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy$219,857
R41 · FY2014 · AR · contact PI
Integrin Alleviation of Muscular Dystrophy$235,014
R01 · FY2012 · AR · contact PI
Congenital Muscular Dystrophy: From Clinical Pathology to Underlying Scientific M$28,460
R13 · FY2012 · AR · contact PI
Integrin Alleviation of Muscular Dystrophy$235,014
R01 · FY2011 · AR · contact PI
Preclinical Testing of Integrin Enhancing Molecules for the Treatment of Muscular$152,280
R21 · FY2011 · AR · contact PI
Integrin Alleviation of Muscular Dystrophy$244,807
R01 · FY2010 · AR · contact PI
Preclinical Testing of Integrin Enhancing Molecules for the Treatment of Muscular$190,350
R21 · FY2010 · AR · contact PI
A drug-based approach for integrin-mediated alleviation of muscular dystrophy$50,000
R21 · FY2010 · NS · contact PI
COBRE: UNR: TARGETED & TRANSGENIC ANIMAL CORE (A): ES CELLS$325,145
P20 · FY2009 · RR · contact PI
Integrin Alleviation of Muscular Dystrophy$247,280
R01 · FY2009 · AR · contact PI
COBRE: UNV MED SCH: P1: INTEGRIN REGULATION OF VASCULAR SMOOTH MUSCLE$193,183
P20 · FY2009 · RR · contact PI
COBRE: UNR: TARGETED & TRANSGENIC ANIMAL CORE (A): ES CELLS$297,620
P20 · FY2008 · RR · contact PI
Integrin Alleviation of Muscular Dystrophy$247,133
R01 · FY2008 · AR · contact PI
A drug-based approach for integrin-mediated alleviation of muscular dystrophy$215,141
R21 · FY2008 · NS · contact PI
COBRE: UNR: TARGETED & TRANSGENIC ANIMAL CORE (A): ES CELLS$293,443
P20 · FY2007 · RR · contact PI
COBRE: UNV MED SCH: P1: INTEGRIN REGULATION OF VASCULAR SMOOTH MUSCLE$226,342
P20 · FY2007 · RR · contact PI
A drug-based approach for integrin-mediated alleviation of muscular dystrophy$122,500
R21 · FY2007 · NS · contact PI
COBRE: UNR: TARGETED & TRANSGENIC ANIMAL CORE (A): ES CELLS$319,984
P20 · FY2006 · RR · contact PI
COBRE: UNV MED SCH: P1: INTEGRIN REGULATION OF VASCULAR SMOOTH MUSCLE$233,102
P20 · FY2006 · RR · contact PI
CORE--COBRE: UNR: TARGETED &TRANSGENIC ANIMAL: ES CELLS$307,016
P20 · FY2005 · RR
COBRE: UNV MED SCH: P1: INTEGRIN REGULATION OF VASCULAR SMOOTH MUSCLE$238,711
P20 · FY2005 · RR
COBRE: UNV MED SCH: P1: INTEGRIN REGULATION OF VASCULAR SMOOTH MUSCLE$238,711
P20 · FY2005 · RR
CORE--COBRE: UNR: TARGETED &TRANSGENIC ANIMAL$345,404
P20 · FY2004 · RR
INTEGRIN REGULATION OF VASCULAR SMOOTH MUSCLE$195,309
P20 · FY2004 · RR